MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00543816

Enrollment

100

Registered

2007-10-15

Start date

2003-08-31

Completion date

2003-11-30

Last updated

2015-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Brief summary

This study will look to see if MK0767 works better than placebo in controlling blood sugar in patients with Type 2 Diabetes who are taking insulin but do not have adequate control of their blood sugar. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Interventions

DRUGMK0767

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Type 2 Diabetes with inadequate glycemic control * Patient is on stable insulin therapy alone or with one oral antidiabetic agent * Male or non-pregnant female 21 years or older * Total daily dose of insulin must be less than or equal to 30 but not greater than or equal to 200 units/day

Exclusion criteria

* Have a history of type 1 diabetes mellitus * History of ketoacidosis who are being treated with insulin * Are taking 2 or more antidiabetic agents in combination with insulin

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026